GW nano school
This article was originally published in The Rose Sheet
George Washington University establishes GW Institute for Nanotechnology, announced Nov. 19. Backed by special endowment funding set aside for academic programs "with the potential for a high level of intellectual distinction," institute will facilitate collaborations among engineering, physics, chemistry and biochemistry faculty members. Sixteen professors are involved in initial projects, including developing a system for nanopatterning and scanning tunneling microscopy, studying growth of carbon nanotubes, creating computational mechanical modeling of nanomaterials, researching nanomagnetics and constructing filtration with nanostructure materials, university says. "National laboratories, federal agencies, and private sector corporations all recognize the as-yet untapped potential for discoveries in this emerging field, and we believe that our engineers and scientists will be among those who unlock some of its exciting secrets," says David Dolling, dean of GW's School of Engineering and Applied Science. While nanotechnology holds great promise in areas ranging "from medicine to electronics to improving water quality worldwide," as Dolling notes, it represents novel risks as well; some consumer groups are calling for tighter FDA oversight and greater transparency from companies (1"The Rose Sheet" Nov. 10, 2008, p. 3)
You may also be interested in...
A Consumers Union report being billed as an exposé of sunscreens that are marketed as nanotech-free but actually contain nanoparticles may signal a need not for FDA's intervention but for industry to take the lead in educating consumers on nanotechnology
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.